10th May 2022 12:01
MaxCyte Inc - Gaithersburg, Maryland-based platform for cell-based research - Says is pleased with positive start to 2022 with "very strong" first-quarter results. For three months to March 31, posts net loss USD4.1 million, narrowed from USD7.1 million last year on revenue of USD11.6 million, up 78% from USD6.5 million. Generates total of USD2.0 million in Strategic Platform License program-related revenue in the first quarter of 2022, compared to immaterial SPL program-related revenue in the first quarter of 2021. For 2022, expects core business revenue to grow at least 25% compared to 2021 core business revenue. It also continues to expect SPL program-related revenue to be around USD4 million in 2022. Read More
